Structure-based tailoring of compound libraries for high-throughput screening: Discovery of novel EphB4 kinase inhibitors

Proteins: Structure, Function and Genetics

Volumn 73, Issue 1, 2008, Pages 11-18

  Kolb, Peter ^a,c   Kipouros, Catherine Berset ^b   Huang, Danzhi ^a   Caflisch, Amedeo ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Oncalis AG   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Cancer; EphB4; Fragment based docking; High throughput screening; Tyrosine kinases

Indexed keywords

ADENOSINE TRIPHOSPHATE; ERYTHROPOIETIN PRODUCING HUMAN HEPATOCELLULAR CARCINOMA RECEPTOR TYROSINE KINASE B 4 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANCHOR BASED LIBRARY TAILORING APPROACH; ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IN VITRO STUDY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CRICETINAE; DRUG DISCOVERY; HUMANS; KINETICS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPHB4; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50849118847     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22028     Document Type: Article

References (43)

1. Vangrevelinghe E, Zimmermann K, Schoepfer J, Portmann R, Fabbro D, Furet P. Discovery of a potent and selective protein kinase ck2 inhibitor by high-throughput docking. J Med Chem 2003;46:2656-2662.
2. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303:1813-1818.
3. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y, Parrish DA, Deschamps JR, Wang S. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005;127:10130-10131.
4. Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A, Zagotto G, Rosolen A, Pinna LA, Meggio F, Moro S. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem 2006;49:2363-2366.
5. Huang D, Lüthi U, Kolb P, Cecchini M, Barberis A, Caflisch A. In silico discovery of β-secretase inhibitors. J Am Chem Soc 2006;128:5436-5443.
6. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177-182.
7. Kraemer O, Hazemann I, Podjarny AD, Klebe G. Virtual screening for inhibitors of human aldose reductase. Proteins: Struct Funct Bioinformatics 2004;55:814-823.
8. Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem 2006;49:3759-3762.
9. Kolb P, Caflisch A. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based highthroughput docking. J Med Chem 2006;49:7384-7392.
10. Majeux N, Scarsi M, Apostolakis J, Ehrhardt C, Caflisch A. Exhaustive docking of molecular fragments with electrostatic solvation. Proteins: Struct Funct Genet 1999;37:88-105.
11. Majeux N, Scarsi M, Caflisch A. Efficient electrostatic solvation model for protein-docking. Proteins: Struct Funct Genet 2001;42:256-268.
12. Budin N, Majeux N, Caflisch A. Fragment-based flexible ligand docking by evolutionary optimization. Biol Chem 2001;382:1365-1372.
13. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins: Struct Funct Genet 1991;11:29-34.
14. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L, Müller K, Schmid G, Tschopp T, van de Waterbeemd H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994;37:3889-3901.
15. Böhm HJ, Böhringer M, Bur D, Gmünder H, Huber W, Klaus W, Kostrewa D, Kühne H, Lübbers T, Meunier-Keller N, Müller F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000;43:2664-2674.
16. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:195-206.
17. Furet P, Bold G, Hofmann F, Manley P, Meyer T, Altmann KH. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg Med Chem Lett 2003;13:2967-2971.
18. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85.
19. Miyazaki Y, Nakano M, Sato H, Truesdale AT, Stuart JD, Nartey EN, Hightower KE, Kane-Carson L. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. Bioorg Med Chem Lett 2007;17:250-254.
20. Milne GWA, Nicklaus MC, Driscoll JS, Wang S, Zaharevitz DW. The NCI drug information system 3D database. J Chem Inf Comput Sci 1994;34:1219-1224.
21. Liao JL. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50:409-424.
22. Cordella L, Foggia P, Sansone C, Vento M. An improved algorithm for matching large graphs. In: Proceedings of the 3rd IAPR TC-15 Workshop on Graph-Based Representations in Pattern Recognition. 2001, Ischia, Italy. pp 149-159.
23. Foggia P. The VFLib Graph Matching Library, version 2.0. http://amalfi.dis.unina.it/graph/db/vflib-2.0/doc/vflib.html
24. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001;106:745-757.
25. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
26. Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
27. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Šali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291-325.
28. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402.
29. Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol 1993;233:123-138.
30. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 1983;4:187-217.
31. Momany FA, Rone R. Validation of the general purpose QUANTA 3.2/CHARMm force field. J Comput Chem 1992;13:888-900.
32. No K, Grant J, Scheraga H. Determination of net atomic charges using a modified partial equalization of orbital electronegativity method. I. Application to neutral molecules as models for polypeptides. J Phys Chem 1990;94:4732-4739.
33. No K, Grant J, Jhon M, Scheraga H. Determination of net atomic charges using a modified partial equalization of orbital electronegativity method. II. Application to ionic and aromatic molecules as models for polypeptides. J Phys Chem 1990;94:4740-4746.
34. Laskowski RA, MacArthur MW, Moss D, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993;26:283-291.
35. Huang D, Caflisch A. Efficient evaluation of binding free energy. J Med Chem 2004;47:5791-5797.
36. Kolb P, Huang D, Dey F, Caflisch A. Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. J Med Chem 2008;51:1179-1188.
37. Aparna V, Rambabu G, Panigrahi SK, Sarma JARP, Desiraju GR. Virtual screening of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions. J Chem Inf Model 2005;45:725-738.
38. Baici A. The specific velocity plot - a graphical method for determining inhibition parameters for both linear and hyperbolic enzyme-inhibitors. Eur J Biochem 1981;119:9-14.
39. Sturz A, Bader B, Thierauch KH, Glienke J. EphB4 signaling is capable of mediating ephrinb2-induced inhibition of cell migration. Biochem Biophys Res Comm 2004;313:80-88.
40. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-431.
41. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 2003;41:1391-1397.
42. Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006;11:607-615.
43. Babaoglu K, Shoichet BK. Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2006;2:720-723.